Company LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
2.73 ^USD	+3.41%		+0.74%	+72.78%

03-20	LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-20	LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Number of employees: 37

USD in Million	2022	Weight	2023	Weight	Delta
Novel Bispecific Antibodies 100.0 %	20	100.0 %	7	100.0 %	-64.09%

USD in Million	2022	Weight	2023	Weight	Delta
Netherlands 100.0 %	20	100.0 %	7	100.0 %	-64.09%

Managers	Title	Age	Since
Stephen Allen Hurly CEO	Chief Executive Officer	56	31/05/19
Fred M. Powell DFI	Director of Finance/CFO	63	31/10/22
Jessica Truscello CTO	Chief Tech/Sci/R&D Officer	-	08/11/21
Hans van der Vliet CTO	Chief Tech/Sci/R&D Officer	50	31/12/16
Charles Q. Morris CTO	Chief Tech/Sci/R&D Officer	59	05/02/23
Paul W. H. I. Parren CTO	Chief Tech/Sci/R&D Officer	60	30/04/18
Robin Hume LAW	General Counsel	-	14/05/23
Wouter van Hunnik HRO	Human Resources Officer	-	08/11/21
Amy Garabedian LAW	General Counsel	-	26/07/21
Peter Ros PRN	Corporate Officer/Principal	52	31/12/19

Members of the board	Title	Age	Since
Stephen Allen Hurly CEO	Chief Executive Officer	56	31/05/19
Karen Wilson BRD	Director/Board Member	61	31/03/21
James Noble BRD	Director/Board Member	65	14/06/22
Peter Kiener BRD	Director/Board Member	72	31/12/22
Jay Backstrom BRD	Director/Board Member	69	14/06/22
Kapil Dhingra CHM	Chairman	64	21/02/21
Mary Wadlinger BRD	Director/Board Member	64	31/12/22
Christy Oliger BRD	Director/Board Member	54	08/03/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	26,289,087	18,738,315 ( 71.28 %)	0	71.28 %

Name	Equities	%	Valuation
Gilde Healthcare Partners BV 20.62 %	5,421,170	20.62 %	18 M $
Versant Venture Management LLC 17.45 %	4,587,837	17.45 %	15 M $
Redmile Group LLC 7.891 %	2,074,372	7.891 %	7 M $
SANOFI 7.301 %	1,919,455	7.301 %	6 M $
Tang Capital Management LLC 3.197 %	840,593	3.197 %	3 M $
Bruce & Co., Inc. 2.936 %	771,874	2.936 %	3 M $
Alpha Wave Global LP 0.4105 %	107,906	0.4105 %	359 327 $
Hans van der Vliet 0.2942 %	77,350	0.2942 %	257 576 $
Amy Garabedian 0.2568 %	67,499	0.2568 %	224 772 $
PNC Financial Services Group, Inc. (13F Subfiler) 0.2473 %	65,000	0.2473 %	216 450 $

LAVA Therapeutics NV

Yalelaan 62

3584 CM, Utrecht

+31 85 016 3100

http://www.lavatherapeutics.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.557 EUR

Average target price

6.684 EUR

Spread / Average Target

+161.37%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
LAVA THERAPEUTICS N.V.	+72.78%	71.77M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research